Migraine Surgery: Current Options and Consensus (2026)

What Is Migraine Surgery?

Surgical Options by Trigger Site

1. Frontal / Supraorbital Trigger (Site I)

• Nerves targeted: Supraorbital and supratrochlear branches of the trigeminal nerve (V1)
• Technique: Endoscopic resection of the corrugator supercilii and procerus muscles, which compress the nerves as they exit the supraorbital foramen
• Trigger identification: Pain at the forehead/glabella; positive response to botulinum toxin injection at this site
• Reported outcomes: ~87% positive response; ~32% complete migraine elimination

2. Temporal Trigger (Site II)

• Nerves targeted: Zygomaticotemporal branch of the trigeminal nerve (ZTBTN) or auriculotemporal nerve (ATN)
• Technique: Neurolysis or deactivation via resection of the overlying temporalis muscle fascia; distinguishing ZTBTN vs ATN is a key surgical decision
• Algorithm (Guyuron 2026, PMID 41891884): Pain anterior to the hairline and frontal co-triggers suggest ZTBTN; preauricular pain suggests ATN. In 151 patients over 25 years: 91% had >50% migraine reduction, 65.7% had complete elimination; re-operation rate was 40% in non-complete responders
• Reported outcomes: ~83-88% positive response; ~50% complete elimination

3. Rhinogenic / Nasal Trigger (Site III)

• Mechanism: Contact between the nasal septum/turbinates and adjacent structures causing mucosal irritation
• Technique: Septoplasty, turbinate reduction, removal of concha bullosa - functionally identical to procedures for nasal obstruction
• Patient selection: Identified by nasal endoscopy or CT showing contact points; migraine triggered by barometric pressure changes or associated with nasal congestion
• Note: This site is sometimes managed by ENT surgeons independently; insurance coverage is more commonly available when functional nasal obstruction is documented

4. Occipital Trigger (Site IV)

• Nerves targeted: Greater occipital nerve (GON), lesser occipital nerve
• Technique: Release from the semispinalis capitis muscle, trapezius fascia, or occipital artery branch compression
• Reported outcomes: ~95% positive response; ~86% complete recovery (highest of all sites, per Raposio data)

5. Lesser-studied / Emerging Sites

• Auriculotemporal nerve (ATN): Increasingly isolated as a distinct temporal target; limited RCT data (as of 2024 Hayes review, no RCTs identified specifically for ATN decompression)
• Sphenopalatine ganglion (SPG) block/ablation: Percutaneous intervention; classified separately from surgical decompression but sometimes grouped under "migraine surgery"
• Neural interconnections: A 2025 anatomical review (PMID 38684023) highlights that extracranial nerves involved in headache surgery have extensive interconnections, with clinical implications for surgical planning and explaining why single-site surgery sometimes fails

Evidence Summary

• Migraine intensity: Significant reduction (p < 0.001), though high heterogeneity (I² = 97.9%)
• Migraine frequency: Significant reduction (p < 0.001), I² = 97.7%
• Migraine duration: Significant reduction (p < 0.001)
• Improvement rates: 68.3%-100% of patients across studies
• Elimination rates: 8.3%-86.5% complete elimination
• Complications: 32.1% reported any complication; most common were transient paresthesia/numbness (12.1%) and itching (4.9%); serious complications were rare

Current Consensus and Controversy

Plastic Surgery Position

Neurology / Headache Medicine Position

• "There are no convincing or definitive data, to date, which show its long-term value"
• Surgery may replace more appropriate treatments
• Side effects can be irreversible
• Surgery should not be done outside of clinical trial settings

Payer/Insurance Consensus (as of 2026)

What Critics Argue

1. Lack of rigorous RCTs: The landmark Guyuron 2009 RCT used a sham surgery comparator (incisions without decompression), which may not adequately control for placebo effect from anesthesia, incisions, and attention
2. High heterogeneity: The I² values in the meta-analysis (>97%) indicate results are not reliably poolable - outcomes vary enormously across studies
3. Selection bias: Most data come from single-surgeon series; the same surgeon selecting, operating, and following up patients inflates apparent success rates
4. Mechanism uncertainty: The peripheral trigger theory is not universally accepted; many neurologists view migraine as a primarily central nervous system disorder where peripheral compression is coincidental

What Proponents Argue

1. Consistent results: Multiple surgeons across multiple centers have replicated Guyuron's results
2. Botox as a predictive test: Patients who respond to botulinum toxin at trigger sites are much more likely to respond to surgery - providing a rational selection tool
3. Unmet need: Refractory chronic migraine remains poorly managed; CGRP antagonists and other newer agents still leave a substantial group without adequate relief
4. Anatomical validation: The 2025 neural interconnection review and decades of cadaveric studies confirm that the proposed compression mechanisms are anatomically plausible

Patient Selection Criteria (Current Practice)

• Diagnosis of refractory chronic migraine (>15 headache days/month despite adequate trials of ≥3 preventive medications)
• Clearly identifiable trigger sites corresponding to anatomy
• Positive response to botulinum toxin injection at the proposed surgical site (generally ≥50% reduction as a prerequisite)
• Adequate trial of medical management including triptans, CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab), and at least two preventive classes
• Psychiatric screening (surgery performs poorly in patients with significant comorbid psychiatric disease)
• No active medication overuse headache (should be treated first)

Bottom Line

• ElHawary et al., 2022 - systematic review and meta-analysis in Annals of Surgery - the strongest current evidence synthesis
• Guyuron et al., 2026 - 25-year temporal migraine algorithm in Plastic and Reconstructive Surgery - latest from the field's originator
• Knoedler et al., 2025 - neural interconnections in headache surgery - anatomical science underpinning the field
• BCBS policy SURG.00096, reviewed Feb 2026 - current payer position

Neuromodulation and RFA for Migraine

1. Non-Invasive Neuromodulation Devices (FDA-Cleared)

Key Points on Non-Invasive Devices

• All five are FDA-cleared and require a prescription
• None require surgery or procedures
• The IHS 2025 guidelines characterize them collectively as "promising alternatives to drug treatment" but acknowledge the evidence base is still maturing
• Cefaly has the most published RCT data; Nerivio has the most recent FDA clearance expansion (pediatric, K241756, October 2024)
• gammaCore is the only device proven in cluster headache - a significant advantage given few treatment options for cluster
• Ontario Health Technology Assessment (2025) specifically reviewed nVNS and found it a reasonable option in cluster headache and migraine
• Insurance coverage is highly variable; most payers still classify them as having limited evidence, though some cover Cefaly and Nerivio under durable medical equipment benefits

2. Invasive / Implantable Neuromodulation

Occipital Nerve Stimulation (ONS)

• Implanted leads over the greater/lesser occipital nerves connected to a subcutaneous pulse generator
• Mechanism: Modulates pain processing at the trigeminal-cervical complex in the spinal cord
• Evidence: American Society of Pain and Neuroscience classified this as Level 1 evidence for chronic migraine (cited in 2026 US DoD consensus guidelines)
• Reality check: Multiple large RCTs (ONSTIM, PRISM) showed mixed results - responder rates were significant but not dramatically superior to sham in intent-to-treat analyses
• Current use: Reserved for refractory chronic migraine after exhausting pharmacological and non-invasive options; FDA has not formally approved ONS for migraine (it is used off-label via the pain indication)
• The Barad et al. 2022 practice guideline (Pain Medicine) gave a weak recommendation for implantable stimulation in chronic migraine prevention

Sphenopalatine Ganglion (SPG) Stimulation

• The Pulsante microstimulator is implanted transorally through the upper gum into the pterygopalatine fossa; activated by an external controller during attacks
• CE-marked in Europe but not FDA-approved in the US
• The ATI trial showed significant acute pain relief and reduced attack frequency in cluster headache; migraine data are more limited
• The Barad 2022 guideline gave it a weak recommendation for chronic migraine prevention

Deep Brain / Hypothalamic Stimulation

• Experimental; used primarily in refractory cluster headache in a small number of European centers; not established for migraine

3. Radiofrequency Ablation (RFA) for Migraine

Types of RFA

• Conventional (thermal) RFA: Heats to 60-80°C; produces a permanent or semi-permanent lesion; high efficacy but irreversible nerve damage
• Pulsed RFA (PRF): Uses short bursts at lower temperatures (42°C); modulates rather than ablates; less destructive, potentially reversible effect - mechanism not fully understood
• Cooled RFA: Uses water-cooled probes allowing larger lesion volumes at lower probe temperatures

RFA Targets in Migraine / Headache

1. Greater occipital nerve (GON) RFA
   • Most commonly used for occipital neuralgia and occipital-dominant headache
   • Evidence is positive in case series but no large sham-controlled RCTs exist
   • UHC policy (2025) acknowledges positive-leaning studies but concludes "further studies are necessary to establish a RFA treatment protocol for headache"
   • Critical finding (PMID 36728939, Casari et al. 2023): When patients who had prior GON-RFA subsequently underwent occipital decompression surgery, 45% had macroscopic nerve damage vs 24% in non-RFA patients. They required more reoperations (27.6% vs 5.8%) and more GON transections (13.8% vs 3.5%) - but ultimately achieved equivalent final outcomes. This means RFA can complicate subsequent surgery if it fails, and patients should be counseled accordingly
2. Sphenopalatine ganglion (SPG) RFA / pulsed RFA
   • Target for cluster headache and migraine with autonomic features
   • Performed under fluoroscopy via a transnasal or infrazygomatic approach
   • An RCT (NCT03567590) specifically evaluating SPG pulsed RFA for cluster headache completed in 2021 - results have been incorporated into payer policy reviews but have not changed coverage determinations
   • Payer coverage: Premera policy (2025) classifies SPG pulsed RFA as investigational
3. Third occipital nerve RFA
   • Used in cervicogenic headache and upper cervical-origin migraine
   • A 2025 case report (PMID 40357069) demonstrated cooled RFA of the third occipital nerve for hemicrania continua - illustrating expanding off-label use but very limited evidence base

Where RFA Currently Stands

• Not covered by major US payers for migraine specifically (classified as investigational)
• Medically necessary per most payers only for cervicogenic headache arising from documented C2-C3 facet joint disease, after positive diagnostic blocks
• Used clinically in interventional pain practices as an off-label bridge or when other options have failed
• The Premera/Wellmark pulsed RFA policy (2025) explicitly states it is investigational for all headache indications due to insufficient RCT evidence

RFA as a Surgical Selection Tool

Summary Table

• Yuan et al. 2025 - IHS non-invasive neuromodulation guidelines - the current international standard
• Barad et al. 2022 - percutaneous interventional guideline - covers GON blocks, SPG blocks, implantable stimulation
• Casari et al. 2023 - RFA impact on subsequent headache surgery - critical for anyone using RFA before considering surgery
• Kissoon et al. 2024 - interventional treatments chapter - comprehensive clinical neurology handbook chapter

Detailed Pathophysiology of Migraine

1. Genetic and Neurobiological Substrate: The Hyperexcitable Brain

• FHM1 - CACNA1A: Encodes the P/Q-type voltage-gated calcium channel. Gain-of-function mutations increase presynaptic calcium entry and glutamate release
• FHM2 - ATP1A2: Encodes the Na⁺/K⁺-ATPase α2 subunit. Loss-of-function reduces astrocytic clearance of K⁺ and glutamate from the synaptic cleft
• FHM3 - SCN1A: Encodes a neuronal voltage-gated sodium channel, normally expressed in inhibitory interneurons - mutations impair inhibitory tone

2. The Prodrome: Hypothalamic and Brainstem Activation

• Posterolateral hypothalamus
• Periaqueductal gray (PAG)
• Midbrain tegmental area
• Dorsal rostral pons

3. Cortical Spreading Depression (CSD): The Aura Mechanism

What is CSD?

• Typically originates in the occipital cortex and spreads anteriorly
• The depolarization wave disrupts ionic gradients: massive efflux of K⁺, influx of Na⁺, Ca²⁺, and Cl⁻ into cells, with water following - cells transiently swell
• Glutamate is released in large quantities during the depolarization wave, activating NMDA receptors and propagating the wave
• The wave does not respect vascular territory boundaries - it crosses the distributions of both the MCA and PCA
• It stops when it reaches major cortical architectural boundaries (e.g., the central sulcus)

Blood flow changes with CSD

1. Brief phase of cortical hyperemia (increased blood flow) - corresponds to the "positive" aura symptoms (scintillations, phosphenes)
2. Prolonged phase of oligemia (reduced blood flow) lasting 60-90 minutes - corresponds to the "negative" symptoms (scotoma, numbness)

Does CSD trigger the headache?

4. The Trigeminovascular System: The Headache Mechanism

Anatomy

• The dura mater and large intracranial vessels are innervated by perivascular sensory fibers from the trigeminal ganglion (predominantly the ophthalmic V1 branch) and from the upper cervical dorsal roots (C1-C2)
• These trigeminal fibers contain and release neuropeptides: CGRP, substance P, neurokinin A, and PACAP
• The meningeal vessels, unlike brain parenchyma, are sensitive to pain - this is why meningeal traction or inflammation causes headache

Peripheral sensitization: neurogenic inflammation

• CGRP (calcitonin gene-related peptide): Potent vasodilator; dilates meningeal arteries; plasma CGRP levels rise during migraine attacks and fall with successful triptan treatment; it is the primary therapeutic target of modern migraine drugs
• Substance P: Promotes mast cell degranulation, increases vascular permeability, and amplifies pain signals
• PACAP (pituitary adenylate cyclase-activating peptide): Emerging as a second key mediator; like CGRP, infusion of PACAP-38 reliably triggers migraine attacks in susceptible individuals; PACAP receptor antibodies (e.g., bocunebart/Lu AG09222) are in Phase IIb trials as of 2026

Signal transmission: the trigeminocervical complex

• Why migraine headache is often felt in the neck and shoulders (convergent referral)
• Why neck manipulation, occipital nerve blocks, or upper cervical interventions can modulate migraine pain

5. CGRP: The Master Mediator

• Produced in: Trigeminal ganglion neurons (peripheral, sensory), brainstem neurons
• Released during: Migraine attacks from perivascular trigeminal fibers
• Actions:
  • Dilation of meningeal and cerebral arteries (via CGRP receptors on smooth muscle and endothelium)
  • Sensitization of trigeminal nociceptors (amplifies pain signals)
  • Promotes mast cell degranulation → further neurogenic inflammation
  • Acts centrally: CGRP receptors in the TCC, trigeminal ganglion, and brainstem
• Evidence for central role:
  • Intravenous CGRP infusion reliably triggers delayed migraine attacks in migraine patients but not controls
  • Plasma CGRP levels are elevated during spontaneous migraine attacks
  • Triptans reduce CGRP release (one of their mechanisms)
  • CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) prevent migraine by blocking CGRP or its receptor
  • Gepants (rimegepant, ubrogepant, zavegepant) treat acute attacks by blocking CGRP receptor

6. Serotonin (5-HT) and the Brainstem Modulatory System

• Platelet and plasma 5-HT levels fluctuate with migraine phases - falling during headache
• Urinary 5-HT and its metabolites are elevated during attacks
• Reserpine and fenfluramine (5-HT releasers) can trigger migraine
• Triptans are 5-HT₁B/₁D agonists, and their efficacy validated the serotonin hypothesis

7. Central Sensitization: Why Migraine Becomes Chronic

Peripheral sensitization (first stage)

Central sensitization (second stage)

• Triptans given early (before allodynia develops) abort the attack effectively
• Triptans given after allodynia develops are far less effective - the central sensitization is already established and less accessible to peripheral vasoconstriction or peripheral CGRP blockade
• This is the physiological basis for the clinical rule: treat migraine early

Chronic migraine

• Medication overuse (paradoxically lowers the pain threshold through opioid-induced hyperalgesia and rebound mechanisms)
• High attack frequency without adequate treatment
• Comorbid sleep disorders, anxiety, depression (all reduce descending pain inhibition)
• Structural changes: neuroimaging studies show iron deposition in the PAG, thalamus, and other areas in chronic migraine - possibly from repeated oxidative stress

8. Neuroinflammation and Glial Involvement (Emerging)

• Astrocytes: Normally regulate extracellular K⁺ and glutamate via transporters (EAAT2) and Na⁺/K⁺-ATPase. In migraine, astrocytic dysfunction → elevated extracellular glutamate → NMDA receptor hyperactivation → facilitates CSD and central sensitization
• Microglia: CSD activates microglia; they adopt an inflammatory phenotype, release cytokines (TNF-α, IL-1β, IL-6), and amplify trigeminal sensitization
• Mast cells in the dura: Degranulate in response to substance P and CSD-released mediators; release histamine, TNF-α, and bradykinin → amplify meningeal nociception

9. Phases Tied to Mechanisms (Summary)

10. The Vascular vs. Neural Debate

• Bradley and Daroff's Neurology in Clinical Practice, Ch. 102 (Pathophysiology of Migraine, pp. 2474-2482)
• Guyton and Hall Textbook of Medical Physiology, Ch. 49 (Headache, p. 616)
• Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 4 (Serotonin and migraine mechanisms)
• PMC: Vessel-to-neuron trigeminovascular hypothesis 2025 - current trigeminovascular debate
• Frontiers in Pharmacology: Gepants and CGRP pathway 2025 - CGRP and CSD overview

Pulsed RFA of the Trigeminal Ganglion for Migraine Prevention

The Critical Distinction First

Rationale: Why the Trigeminal Ganglion Is a Rational Target in Migraine

• CGRP and substance P are synthesized and stored in trigeminal ganglion neurons and released peripherally from their axonal terminals onto meningeal vessels
• Sensitization of these cell bodies lowers the threshold for pain signaling throughout the V1-V3 distribution
• Botulinum toxin works partly by reaching trigeminal ganglion cell bodies via retrograde axonal transport and reducing neuropeptide release
• Blocking, modulating, or reducing output from the ganglion should theoretically reduce both peripheral neurogenic inflammation and the afferent load to the trigeminocervical complex

• Upregulate inhibitory c-fos expression in dorsal horn neurons
• Reduce pro-inflammatory cytokines (TNF-α, IL-1β) at the treated site
• Induce long-term potentiation of inhibitory interneurons
• Reduce sodium channel expression and axonal excitability

Evidence for PRF of the Trigeminal Ganglion in Migraine Specifically

1. Indirect Support: PRF of Trigeminal Branches (Not Ganglion)

• PRF at various trigeminal branch targets (supraorbital, infraorbital, auriculotemporal) showed positive outcomes in case series
• The review concluded evidence is low quality (mostly retrospective, heterogeneous targets and parameters) but supports analgesic benefit
• Optimal PRF target and settings remain unclear

2. PRF of the Greater Occipital Nerve (GON) for Chronic Migraine

• Lesion RFA: 83% responder rate at 12 months, 5-day reduction in monthly migraine days
• Pulsed RFA: 65% responder rate at 12 months
• PRF also improved depression and sleep disturbance scores in migraine patients
• Efficacy was reduced in patients with comorbid anxiety or fibromyalgia (central sensitization subgroup)

3. PRF of the Gasserian Ganglion in Trigeminal Neuralgia

• 1-year response rate: 73.1% PRF vs 32.8% nerve block (p<0.001)
• No difference in adverse events between groups
• Supports high-voltage PRF at the ganglion as effective for trigeminal pain

• 12-month responder rate: 83.6% (combined) vs 67.1% (PRF alone) (p=0.021)
• The combined approach adds modest thermal lesioning on top of PRF - more effective but slightly more facial numbness (transient in most cases)
• PRF alone at 42°C, 70V, 600 seconds: 67% 12-month response in TN

Head-to-Head: PRF vs Conventional RFA at the Gasserian Ganglion

• CRF showed significantly greater pain relief at 3 and 6 months
• Satisfaction scores higher in CRF group
• Conclusion: CRF more effective for long-term relief; PRF preferred when nerve preservation is prioritized (e.g., patients who cannot tolerate numbness or who need a reversible approach before committing to more destructive procedures)

Safety Profile: Why PRF Is Attractive at This Target

• Facial numbness/hypoesthesia (40%+ of cases)
• Anesthesia dolorosa (deafferentation pain - potentially worse than the original pain)
• Corneal anesthesia with risk of neurotrophic keratitis
• Masseter weakness

• Transient dysesthesia: rare (~5% in combined PRF+CRF; near zero for PRF alone)
• No reported cases of anesthesia dolorosa with PRF alone at the ganglion
• Repeatable - can be performed multiple times as effects wane
• Can bridge patients to more definitive treatment (MVD, thermocoagulation, Gamma Knife)

Practical Position and Clinical Summary

Bottom line

1. PRF at adjacent trigeminal system targets (GON, branches) showing benefit in migraine
2. PRF at the Gasserian ganglion showing efficacy in trigeminal neuralgia

• Jia et al. 2023 - multicenter RCT high-voltage PRF for TN, J Headache Pain
• Zhao et al. 2025 - RCT PRF vs PRF+CRF at Gasserian ganglion, J Neurosurg
• Jitsinthunun et al. 2025 - PRF evidence review, Pain Physician
• Gasserian PRF vs peripheral PRF comparison 2025, JOFPH